Related Experiment Videos
Tobramycin population pharmacokinetics in neonates
M de Hoog1, R C Schoemaker, J W Mouton
1Department of Pediatrics, Erasmus University, Rotterdam, The Netherlands. dehoog@alkg.azr.nl
Clinical Pharmacology and Therapeutics
|November 14, 1997
Summary
This study proposes a new tobramycin dosing schedule for neonates based on gestational age to ensure therapeutic peak levels and minimize toxicity. The optimized regimen improves drug safety and efficacy in newborns.
Area of Science:
- Neonatal pharmacology
- Pediatric pharmacokinetics
- Antibiotic dosing optimization
Background:
- Neonatal sepsis requires effective antibiotic treatment.
- Optimizing tobramycin dosing is crucial for efficacy and safety in neonates.
- Current dosing regimens may lead to subtherapeutic or toxic drug levels.
Purpose of the Study:
- To establish an evidence-based tobramycin dosing schedule for neonates.
- To tailor dosing to different gestational ages.
- To achieve therapeutic peak and minimize trough tobramycin levels.
Main Methods:
- Retrospective analysis of 470 neonates with suspected septicemia.
- Prospective validation in 23 neonates.
- Population pharmacokinetic modeling using NONMEM software.
- Analysis of tobramycin peak and trough serum levels.
Main Results:
- Initial dosing resulted in 19.1% of peak and 32.8% of trough levels outside the therapeutic range.
- Proposed regimen: <32 weeks GA: 4 mg/kg q48h; 32-37 weeks GA: 4 mg/kg q36h; >37 weeks GA: 4 mg/kg q24h.
- Predicted peak levels >5 mg/L in 95.1%; predicted trough levels >2 mg/L in 1.9% of neonates.
Conclusions:
- The proposed tobramycin dosing schedule optimizes therapeutic efficacy.
- This regimen minimizes the risk of toxicity by controlling trough levels.
- Gestational age-specific dosing is essential for safe and effective neonatal care.